Hannig Jürgen, Siekmeier Rüdiger
Drug Regulatory Affairs, Pharmaceutical Institute, University Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Adv Exp Med Biol. 2015;873:87-100. doi: 10.1007/5584_2015_165.
The current European system governed by the three EC directives 93/42/EEC (Medical Device Directive), 98/79/EC (In-Vitro Diagnostic Directive) and 90/385/EEC (Active Implantable Medical Device Directive) regulates marketing and post-market surveillance of medical devices in the European Economic Area (EEA). In cases of incidents raising the field safety corrective actions (FSCA), manufacturers have to inform the responsible Competent Authority (CA; in Germany this is the Federal Institute for Drugs and Medical Devices, BfArM) and the public by field safety notices (FSN). In this study we analyzed FSN of respirators and consumables directly required for their function, whereas devices for anesthesia and gas delivery were excluded. FSCA and FSN of 2005-2013 publicized by BfArM for the included products were analyzed with respect to the MEDDEV 2.12-1 rev. 8. In total, 60 FSCA were publicized. German and English FSN were found in 59/53 cases, respectively. FSN were clearly characterized as FSN in 44/38 cases and declaration of the type of action in 45/44 cases, respectively. Product names were provided in all cases. Lot numbers or other information for product characterization were available in 7/7 and 43/40 cases, respectively. Detailed information regarding FSCA and product malfunction was found in all cases. Information on product related risks with previous use of affected devices was provided in 42/38 cases. In 53/53 cases manufacturers provided information to mitigate product related risks. Requests to pass FSN to persons needing awareness in the organization were found in 27/24 cases. Contact data were provided in 53/48 cases, respectively. Confirmation that a CA was informed was found in 28/26 cases and in 19/15 cases a customer confirmation was included. The identified risks were: total loss of function (19/16), short circuit (1/1) and burn (3/3), and inhalation of foreign particles (1/1) which might cause severe risk to patients and users. The most frequent FSCA were product modifications and customer information. The data suggest that there is an annually increasing number of FSCA on devices included in our study. Most FSN fulfill the criteria of MEDDEV 2.12-1 rev. 8. However, there are differences between German and English FSN, e.g., regarding the distribution to persons needing awareness, missing statement that a CA was informed, and missing customer confirmation. Due to the importance of FSN for reduction of product related risks in FSCA, the type and content of FSN should be further improved.
当前欧洲体系由三项欧盟指令(93/42/EEC《医疗器械指令》、98/79/EC《体外诊断医疗器械指令》和90/385/EEC《有源植入式医疗器械指令》)管辖,对欧洲经济区(EEA)内医疗器械的上市和上市后监督进行规范。在发生引发现场安全纠正措施(FSCA)的事件时,制造商必须通过现场安全通知(FSN)告知负责的主管当局(CA;在德国为联邦药品和医疗器械研究所,BfArM)及公众。在本研究中,我们分析了呼吸器及其功能直接所需耗材的FSN,而麻醉和气体输送设备被排除在外。对BfArM在2005 - 2013年公布的所涉产品的FSCA和FSN,按照MEDDEV 2.12 - 1修订版8进行了分析。总共公布了60项FSCA。分别在59/53例中发现了德语和英语的FSN。在分别44/38例中,FSN被明确界定为FSN,在45/44例中声明了行动类型。所有案例均提供了产品名称。分别在7/(此处原文可能有误,推测应为7/7)和43/40例中提供了批号或其他产品特征信息。在所有案例中都发现了关于FSCA和产品故障的详细信息。在42/38例中提供了与受影响设备先前使用相关的产品风险信息。在53/53例中,制造商提供了降低产品相关风险的信息。在分别27/24例中发现了将FSN传达给组织内需要知晓的人员的请求。分别在53/48例中提供了联系数据。在28/26例中发现已通知CA的确认信息,在19/15例中包含了客户确认信息。识别出的风险有:功能完全丧失(19/16)、短路(1/1)、烧伤(3/3)以及吸入异物(1/1),这可能对患者和使用者造成严重风险。最常见的FSCA是产品改进和客户信息。数据表明,我们研究中所涉设备的FSCA数量逐年增加。大多数FSN符合MEDDEV 2.12 - 1修订版8的标准。然而,德语和英语FSN之间存在差异,例如,在传达给需要知晓的人员方面、未声明已通知CA以及缺少客户确认方面。鉴于FSN对于降低FSCA中与产品相关风险的重要性,FSN的类型和内容应进一步改进。